BackCytoMed Therapeutics Overview

CytoMed Therapeutics Current Assets

Track CytoMed Therapeutics's current assets ($3.7M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$3.66M
16.73% YoYΔ $-735722.00 vs prior year quarter

Peer trimmed avg / median

Loading

CytoMed Therapeutics Current Assets History

Loading

CytoMed Therapeutics vs. peers: Current Assets Comparison

Loading

CytoMed Therapeutics Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

CytoMed Therapeutics (GDTC) FAQ

The latest current assets for GDTC is $3.7M as of December 2025. That compares with $4.4M in the prior-year period — down 16.7% year over year. Investors often review this figure alongside CytoMed Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, GDTC's current assets moved from $4.4M to $3.7M — a 16.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CytoMed Therapeutics's operating scale or balance-sheet position.

A current assets figure of $3.7M for GDTC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GDTC's current assets ($3.7M), review year-over-year change from $4.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.